Cebrero-Cangueiro, T. Nordmann, Patrice Carretero-Ledesma, M. Pachón, J. Pachón-Ibáñez, M. E. 2020-11-23 Objectives: To evaluate the in vivo efficacy of a dual carbapenem combination containing imipenem plus meropenem against carbapenem-resistant Acinetobacter baumannii producing carbapenemases OXA-23 or OXA-58.Methods: An experimental model of peritonitis using C57BL/6J female mice was developed and the minimum lethal doses were calculated for infections due to OXA-23 or OXA-58 producers of A. baumannii clinical isolates. The efficacies of the carbapenems in monotherapy and in combination were tested.Results: Meropenem was better than imipenem in mice infected with either of the carbapenem-resistant A. baumannii (CRAb) strains. The combination of meropenem plus imipenem significantly improved the clearance of CRAbs from spleen compared with non-treated groups. The carbapenem-containing combination was better than imipenem for treating mice infected with both carbapenemase producers. In blood, the carbapenem combination significantly decreased the bacterial load of the OXA-23 producers compared with imipenem or meropenem used in monotherapy.Conclusions: These results suggest that dual carbapenem combination could be an option for the treatment of infections due to carbapenemase-producing A. baumannii such as OXA-23 and OXA-58 producers. application/pdf https://folia.unifr.ch/global/documents/309240 https://folia.unifr.ch/documents/309240/files/nor_edc.pdf eng info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkaa487 info:eu-repo/semantics/openAccess License undefined Journal of Antimicrobial Chemotherapy. - 2020, p. dkaa487 info:eu-repo/classification/udc/57 Efficacy of dual carbapenem treatment in a murine sepsis model of infection due to carbapenemase-producing Acinetobacter baumannii http://purl.org/coar/resource_type/c_6501